Deferasirox in the management of iron overload in patients with myelofibrosis treated with ruxolitinib: The multicentre retrospective RUX‐IOL study Redazione 24 Febbraio 2022 ...
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma Redazione 24 Febbraio 2022 ...
Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE Redazione 3 Febbraio 2022 ...
The Blood Proteoform Atlas: A reference map of proteoforms in human hematopoietic cells Redazione 3 Febbraio 2022 ...
COVID‐19 infection in chronic myeloid leukaemia after one year of the pandemic in Italy. A Campus CML report Redazione 3 Febbraio 2022 ...
Betibeglogene Autotemcel Gene Therapy for Non–β0/β0 Genotype β-Thalassemia Redazione 3 Febbraio 2022 ...
Distinguishing AML from MDS: a fixed blast percentage may no longer be optimal Redazione 27 Gennaio 2022 ...
Quality-of-life analysis of pembrolizumab vs brentuximab vedotin for relapsed/refractory classical Hodgkin lymphoma Redazione 27 Gennaio 2022 ...
Impact of ruxolitinib on survival of patients with myelofibrosis in the real world: update of the ERNEST Study Redazione 27 Gennaio 2022 ...